José Ignacio
Herrero Santos
Consultor Médico
Clínica Universitaria de Navarra
Pamplona, EspañaPublicacions en col·laboració amb investigadors/es de Clínica Universitaria de Navarra (88)
2024
-
Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment
Journal of Physiology and Biochemistry
-
New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5
-
The Impact of Portal Hypertension Assessment Method on the Outcomes of Hepatocellular Carcinoma Resection: A Meta-Analysis of Matched Cohort and Prospective Studies
Annals of Surgery, Vol. 280, Núm. 1, pp. 46-55
2021
-
Web-based formative assessment through clinical cases: role in pathophysiology teaching
BMC Medical Education, Vol. 21, Núm. 1
2019
-
Association between Different Animal Protein Sources and Liver Status in Obese Subjects with Non-Alcoholic Fatty Liver Disease: Fatty Liver in Obesity (FLiO) Study
Nutrients, Vol. 11, Núm. 10
-
Efficacy and safety of long-term use of tedizolid after liver transplantation in an adolescent with pulmonary tuberculosis
Journal of Antimicrobial Chemotherapy
-
Immunophenotypic Pattern of De Novo Malignancy After Liver Transplantation
Transplantation Proceedings, Vol. 51, Núm. 1, pp. 77-79
-
Ultrasound/elastography techniques, lipidomic and blood markers compared to magnetic resonance imaging in non-alcoholic fatty liver disease adults
International Journal of Medical Sciences, Vol. 16, Núm. 1, pp. 75-83
2018
-
Interplay of glycemic index, glycemic load, and dietary antioxidant capacity with insulin resistance in subjects with a cardiometabolic risk profile
International Journal of Molecular Sciences, Vol. 19, Núm. 11
-
Treatment of graft-versus-host disease with mesenchymal cells as a complication of a liver transplantation
Revista Española de Enfermedades Digestivas, Vol. 110, Núm. 11, pp. 734 - 736
2017
-
Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation
Journal of Hepatology, Vol. 67, Núm. 6, pp. 1168-1176
-
Conversion from calcineurin Inhibitor-Based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation
Annals of Transplantation, Vol. 22, pp. 141-147
-
Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study
Transplant International, Vol. 30, Núm. 10, pp. 1041-1050
-
Real-world multicenter experience of immunosuppression minimization among 661 liver transplant recipients
Annals of Transplantation, Vol. 22, pp. 265-275
-
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Hepatology, Vol. 65, Núm. 6, pp. 1810-1822
2016
-
Controlling Diabetes after Liver Transplantation: Room for Improvement
Transplantation, Vol. 100, Núm. 10, pp. e66-e73
-
Impact of cytomegalovirus infection on severe hepatitis c recurrence in patients undergoing liver transplantation
Transplantation, Vol. 100, Núm. 3, pp. 593-599
-
Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations
Transplantation Reviews, Vol. 30, Núm. 3, pp. 119-143
2015
-
Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey
Clinical Microbiology and Infection, Vol. 21, Núm. 6, pp. 604.e1-604.e9
-
Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients
Clinical Transplantation, Vol. 29, Núm. 8, pp. 667-677